We serve Chemical Name:N-(1-hydroxy-2-phenyl-6,7-dihydro-5H-benzimidazol-4-ylidene)hydroxylamine CAS:175136-52-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(1-hydroxy-2-phenyl-6,7-dihydro-5H-benzimidazol-4-ylidene)hydroxylamine
CAS.NO:175136-52-4
Synonyms:1-hydroxy-2-phenyl-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-4-one oxime
Molecular Formula:C13H13N3O2
Molecular Weight:243.26100
HS Code:
Physical and Chemical Properties:
Melting point:270ºC
Boiling point:562.1ºC at 760 mmHg
Density:1.42g/cm3
Index of Refraction:1.705
PSA:70.64000
Exact Mass:243.10100
LogP:2.30200
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-hydroxy-2-phenyl-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-4-one oxime chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-hydroxy-2-phenyl-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-4-one oxime physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-hydroxy-2-phenyl-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-4-one oxime Use and application,1-hydroxy-2-phenyl-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-4-one oxime technical grade,usp/ep/jp grade.
Related News: Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms including pain, rashes, fatigue, swelling in joints and fevers. Cyclopenta[c][1]benzopyran-4(1H)-one,2,3,3a,9b-tetrahydro-3a-(hydroxymethyl)-8,9b-dimethyl-, (3aR,9bR)-rel- manufacturers Onyx Scientific, a small molecule API contract development and manufacturing organization (CDMO) has received a commercial API license for its UK facility. 4-benzyloxy-2,3-dimethylbutan-2-ol suppliers The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered. N-{5-benzoylaminocarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl}-o-anisic amide vendor & factory.
